Xintong Pharmacy Company Report issue

Government Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02623569
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

pradefovir (1 trial)

tenofovir (viread) (3 trials)

Drugs in Phase 2 Trials (4)

atenolol (tenormin) (1 trial)

ivabradine (corlanor) (1 trial)

mb07133 (2 trials)

sintilimab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 2)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Herpesviridae Infections (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6